We are developing muscle biology-directed potential medicines to improve the healthspan of people with devastating diseases of impaired muscle function
and conditions of muscle weakness
associated with aging.
Six Minute Walk Test Acceptable as Primary Efficacy Endpoint for Potential Registration Program SOUTH SAN FRANCISCO, Calif. , Jan. 22, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it has received feedback from the U.S....READ MORE ›
People fighting amyotrophic lateral sclerosis have few treatment options; we are dedicated to changing the progression of this fatal disease.
Heart failure death and disability rates continue to rise, despite current treatment options. With Amgen, we are developing a novel therapy that may improve cardiac performance in people with heart failure.
People suffering from spinal muscular atrophy experience devastating loss of muscle function. With Astellas, we are working on a treatment that may enhance skeletal muscle performance in these and other patients.